FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3113251146> ?p ?o ?g. }

• W3113251146 endingPage "111073" @default.
• W3113251146 startingPage "111073" @default.
• W3113251146 abstract "Sepsis is a life-threatening condition often leading to multiple organ failure for which currently no pharmacological treatment is available. Endothelial cells (EC) are among the first cells to respond to pathogens and inflammatory mediators in sepsis and might be a sentinel target to prevent the occurrence of multiple organ failure. Lipopolysaccharide (LPS) is a Gram-negative bacterial component that induces endothelial expression of inflammatory adhesion molecules, cytokines, and chemokines. This expression is regulated by a network of kinases, the result of which in vivo enables leukocytes to transmigrate from the blood into the underlying tissue, causing organ damage. We hypothesised that besides the known kinase pathways, other kinases are involved in the regulation of EC in response to LPS, and that these can be pharmacologically targeted to inhibit cell activation. Using kinome profiling, we identified 58 tyrosine kinases (TKs) that were active in human umbilical vein endothelial cells (HUVEC) at various timepoints after stimulation with LPS. These included AXL tyrosine kinase (Axl), focal adhesion kinase 1 (FAK1), and anaplastic lymphoma kinase (ALK). Using siRNA-based gene knock down, we confirmed that these three TKs mediate LPS-induced endothelial inflammatory activation. Pharmacological inhibition with FAK1 inhibitor FAK14 attenuated LPS-induced endothelial inflammatory activation and leukocyte adhesion partly via blockade of NF-κB activity. Administration of FAK14 after EC exposure to LPS also resulted in inhibition of inflammatory molecule expression. In contrast, inhibition of ALK with FDA-approved inhibitor Ceritinib attenuated LPS-induced endothelial inflammatory activation via a pathway that was independent of NF-κB signalling while it did not affect leukocyte adhesion. Furthermore, Ceritinib administration after start of EC exposure to LPS did not inhibit inflammatory activation. Combined FAK1 and ALK inhibition attenuated LPS-induced endothelial activation in an additive manner, without affecting leukocyte adhesion. Summarising, our findings suggest the involvement of FAK1 and ALK in mediating LPS-induced inflammatory activation of EC. Since pharmacological inhibition of FAK1 attenuated endothelial inflammatory activation after the cells were exposed to LPS, FAK1 represents a promising target for follow up studies." @default.
• W3113251146 created "2020-12-21" @default.
• W3113251146 creator A5037487077 @default.
• W3113251146 creator A5044719945 @default.
• W3113251146 creator A5045103912 @default.
• W3113251146 creator A5046267469 @default.
• W3113251146 creator A5047572993 @default.
• W3113251146 creator A5072711933 @default.
• W3113251146 creator A5074349116 @default.
• W3113251146 creator A5079902714 @default.
• W3113251146 date "2021-01-01" @default.
• W3113251146 modified "2023-10-17" @default.
• W3113251146 title "Pharmacological inhibition of focal adhesion kinase 1 (FAK1) and anaplastic lymphoma kinase (ALK) identified via kinome profile analysis attenuates lipopolysaccharide-induced endothelial inflammatory activation" @default.
• W3113251146 cites W1507221188 @default.
• W3113251146 cites W1551653695 @default.
• W3113251146 cites W1899433760 @default.
• W3113251146 cites W1968201168 @default.
• W3113251146 cites W1976928250 @default.
• W3113251146 cites W1979452780 @default.
• W3113251146 cites W1996643996 @default.
• W3113251146 cites W2008680963 @default.
• W3113251146 cites W2035809865 @default.
• W3113251146 cites W2038586807 @default.
• W3113251146 cites W2070460007 @default.
• W3113251146 cites W2074070818 @default.
• W3113251146 cites W2080139795 @default.
• W3113251146 cites W2099912006 @default.
• W3113251146 cites W2100235578 @default.
• W3113251146 cites W2112251628 @default.
• W3113251146 cites W2114876832 @default.
• W3113251146 cites W2126476434 @default.
• W3113251146 cites W2134232468 @default.
• W3113251146 cites W2136608321 @default.
• W3113251146 cites W2155207597 @default.
• W3113251146 cites W2280404143 @default.
• W3113251146 cites W2343398349 @default.
• W3113251146 cites W2508485797 @default.
• W3113251146 cites W2528023612 @default.
• W3113251146 cites W2727319405 @default.
• W3113251146 cites W2764184942 @default.
• W3113251146 cites W2765364205 @default.
• W3113251146 cites W2767782617 @default.
• W3113251146 cites W2768998507 @default.
• W3113251146 cites W2787992873 @default.
• W3113251146 cites W2798130810 @default.
• W3113251146 cites W2945006733 @default.
• W3113251146 cites W2945560448 @default.
• W3113251146 doi "https://doi.org/10.1016/j.biopha.2020.111073" @default.
• W3113251146 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33378972" @default.
• W3113251146 hasPublicationYear "2021" @default.
• W3113251146 type Work @default.
• W3113251146 sameAs 3113251146 @default.
• W3113251146 citedByCount "6" @default.
• W3113251146 countsByYear W31132511462021 @default.
• W3113251146 countsByYear W31132511462022 @default.
• W3113251146 countsByYear W31132511462023 @default.
• W3113251146 crossrefType "journal-article" @default.
• W3113251146 hasAuthorship W3113251146A5037487077 @default.
• W3113251146 hasAuthorship W3113251146A5044719945 @default.
• W3113251146 hasAuthorship W3113251146A5045103912 @default.
• W3113251146 hasAuthorship W3113251146A5046267469 @default.
• W3113251146 hasAuthorship W3113251146A5047572993 @default.
• W3113251146 hasAuthorship W3113251146A5072711933 @default.
• W3113251146 hasAuthorship W3113251146A5074349116 @default.
• W3113251146 hasAuthorship W3113251146A5079902714 @default.
• W3113251146 hasBestOaLocation W31132511461 @default.
• W3113251146 hasConcept C117643217 @default.
• W3113251146 hasConcept C126322002 @default.
• W3113251146 hasConcept C13373296 @default.
• W3113251146 hasConcept C184235292 @default.
• W3113251146 hasConcept C203014093 @default.
• W3113251146 hasConcept C2776232967 @default.
• W3113251146 hasConcept C2776914184 @default.
• W3113251146 hasConcept C2778754761 @default.
• W3113251146 hasConcept C2779634585 @default.
• W3113251146 hasConcept C42362537 @default.
• W3113251146 hasConcept C502942594 @default.
• W3113251146 hasConcept C54174078 @default.
• W3113251146 hasConcept C62478195 @default.
• W3113251146 hasConcept C71924100 @default.
• W3113251146 hasConcept C86803240 @default.
• W3113251146 hasConcept C95444343 @default.
• W3113251146 hasConcept C98274493 @default.
• W3113251146 hasConceptScore W3113251146C117643217 @default.
• W3113251146 hasConceptScore W3113251146C126322002 @default.
• W3113251146 hasConceptScore W3113251146C13373296 @default.
• W3113251146 hasConceptScore W3113251146C184235292 @default.
• W3113251146 hasConceptScore W3113251146C203014093 @default.
• W3113251146 hasConceptScore W3113251146C2776232967 @default.
• W3113251146 hasConceptScore W3113251146C2776914184 @default.
• W3113251146 hasConceptScore W3113251146C2778754761 @default.
• W3113251146 hasConceptScore W3113251146C2779634585 @default.
• W3113251146 hasConceptScore W3113251146C42362537 @default.
• W3113251146 hasConceptScore W3113251146C502942594 @default.
• W3113251146 hasConceptScore W3113251146C54174078 @default.
• W3113251146 hasConceptScore W3113251146C62478195 @default.
• W3113251146 hasConceptScore W3113251146C71924100 @default.
• W3113251146 hasConceptScore W3113251146C86803240 @default.

• next